119th Congress · introduced in the Senate · Jun 4, 2026
Homeopathic Drug Product Safety, Quality, and Transparency Act
Official title from Congress.gov
Latest action (Jun 4, 2026): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
4 citations.
AMERICANS FOR HOMEOPATHY CHOICE ACTION · lobbying firm or registrant: VENABLE LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Health Issues
$50,000
Paid to lobbying firm
Issues relating to the regulation of homeopathic medicine; H.R. 7050 / S.4692 - Homeopathic Drug Product Safety, Quality, and Transparency Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CENTER FOR INQUIRY, INC. OFFICE OF PUBLIC POLICY · lobbying firm or registrant: CENTER FOR INQUIRY, INC. OFFICE OF PUBLIC POLICY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 12, 2026 · issue area: Science/Technology
Amount not reported
CFI's Office of Public Policy lobbied against S. 4692, the "Homeopathic Drug Product Safety, Quality, and Transparency Act." This legislation would allow lax federal regulation of the homeopathy industry, using ho…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
AMERICANS FOR HOMEOPATHY CHOICE ACTION · lobbying firm or registrant: VENABLE LLP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Health Issues
$50,000
Paid to lobbying firm
Issues relating to the regulation of homeopathic medicine; H.R. 7050 / S.4692 - Homeopathic Drug Product Safety, Quality, and Transparency Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CENTER FOR INQUIRY, INC. OFFICE OF PUBLIC POLICY · lobbying firm or registrant: CENTER FOR INQUIRY, INC. OFFICE OF PUBLIC POLICY
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 16, 2026 · issue area: Science/Technology
Amount not reported
CFI's Office of Public Policy lobbied against S. 4692, the "Homeopathic Drug Product Safety, Quality, and Transparency Act." This legislation would allow lax federal regulation of the homeopathy industry, using ho…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing